Art. -Nr.: HY-148570

PHGDH-IN-3

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-3 inhibits PHGDH with an IC₅₀ value of 2.8 μM. PHGDH-IN-3 can be used for the research of cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.34%
CAS. Nr.: 2893778-31-7
Formel: C₂₄H₁₈FN₃O₄S₂
Molecular Weight:495.55

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

PHGDH-IN-3 Chemical Structure

CAS. Nr.: 2893778-31-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 2.8 μM (PHGDH)^[1].
Kd: 2.33 μM (PHGDH)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
BT-20	IC₅₀	5.3 μM Compound: D8	Antiproliferative activity against human BT-20 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human BT-20 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]
HCC827	IC₅₀	21.6 μM Compound: D8	Antiproliferative activity against human HCC827 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human HCC827 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]
HCT-116	IC₅₀	9.6 μM Compound: D8	Antiproliferative activity against human HCT-116 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]
MCF-10A	IC₅₀	52.9 μM Compound: D8	Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]
MCF7	IC₅₀	39.2 μM Compound: D8	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]
MDA-MB-231	IC₅₀	37.1 μM Compound: D8	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]
MDA-MB-468	IC₅₀	5.3 μM Compound: D8	Antiproliferative activity against human MDA-MB-468 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-468 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]
NCI-H1975	IC₅₀	6.2 μM Compound: D8	Antiproliferative activity against human NCI-H1975 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]
NCI-H23	IC₅₀	28.6 μM Compound: D8	Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]
PANC-1	IC₅₀	36.6 μM Compound: D8	Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]
PC-9	IC₅₀	3.5 μM Compound: D8	Antiproliferative activity against human PC-9 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human PC-9 cells expressing PHGDH assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]
ZR-75-1	IC₅₀	38.3 μM Compound: D8	Antiproliferative activity against human ZR-75-1 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay Antiproliferative activity against human ZR-75-1 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay	[PMID: 36594670]

In Vitro

PHGDH-IN-3 (compound D8) has good enzymatic inhibitory activity with an IC₅₀ value of 2.8 μM^[1].
PHGDH-IN-3 has high binding affinity for the PHGDH protein with a K_d value of 2.33 μM^[1].
PHGDH-IN-3 has sensitivity to the cell lines with the PHGDH gene amplification or overexpression^[1].
PHGDH-IN-3 can restrict the de novo serine synthesis from glucose within MDA-MB-468 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PHGDH-IN-3 (compound D8) (p.o., i.v.; 1, 3 mg/kg) exhibits excellent in vivo pharmacokinetic properties^[1].
PHGDH-IN-3 (i.p.; 12.5, 25, 50 mg/kg; once daily for consecutive 31 days) exertes evident antitumor efficacy in the PC9 xenograft mouse model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICR mice^[1]
Dosage:

1, 3 mg/kg
Administration:

Oral (p.o.) and intravenous (i.v.) administration

Result:

PK parameters	i.v. (1 mg/kg)	p.o. (3 mg/kg)
AUC (h•ng/mL)	38,358 ± 14,768	94,386 ± 23,416
T_1/2(h)	4.94 ± 0.38	4.74 ± 0.30
T_max (h)		3.33 ± 1.15
CL_{_obs}(mL/min/kg)	0.48 ± 0.23
C_max(ng/mL)		8842 ± 1755
F (%)		82.0

Animal Model:

Balb/c nude mice^[1]
Dosage:

12.5, 25, 50 mg/kg
Administration:

Intraperitoneal (i.p.); once daily for consecutive 31 days
Result:

Exhibited an in vivo anti-tumor effect and significantly delayed the tumor growth.
Significantly abated the tumor weights of mice at 25 mg/ kg.

Chemical Information

CAS. Nr. 2893778-31-7
Appearance Solid
Molecular Weight 495.55
Formel C₂₄H₁₈FN₃O₄S₂
Color Off-white to light brown
SMILES

CC(C1=CC=CC(NS(=O)(C2=CC=C(C=C2)C(NC3=NC(C4=CC=CC(F)=C4)=CS3)=O)=O)=C1)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Genesis

Generation of Myeloid-Specific Bmal1 Knockout Mice and Identification of Bmal1-Regulated Ferroptosis in Macrophages. [Abstract]

2025 Apr;63(2):e70014. PMID: 40197722

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (201.80 mM; ultrasonic and warming and heat to 70°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0180 mL

10.0898 mL

20.1796 mL

5 mM

0.4036 mL

2.0180 mL

4.0359 mL

10 mM

0.2018 mL

1.0090 mL

2.0180 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (10.09 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Dingding Gao, et al. Discovery of Novel Drug-like PHGDH Inhibitors to Disrupt Serine Biosynthesis for Cancer Therapy. J Med Chem. 2023 Jan 12;66(1):285-305. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0180 mL	10.0898 mL	20.1796 mL	50.4490 mL
	5 mM	0.4036 mL	2.0180 mL	4.0359 mL	10.0898 mL
	10 mM	0.2018 mL	1.0090 mL	2.0180 mL	5.0449 mL
	15 mM	0.1345 mL	0.6727 mL	1.3453 mL	3.3633 mL
	20 mM	0.1009 mL	0.5045 mL	1.0090 mL	2.5224 mL
	25 mM	0.0807 mL	0.4036 mL	0.8072 mL	2.0180 mL
	30 mM	0.0673 mL	0.3363 mL	0.6727 mL	1.6816 mL
	40 mM	0.0504 mL	0.2522 mL	0.5045 mL	1.2612 mL
	50 mM	0.0404 mL	0.2018 mL	0.4036 mL	1.0090 mL
	60 mM	0.0336 mL	0.1682 mL	0.3363 mL	0.8408 mL
	80 mM	0.0252 mL	0.1261 mL	0.2522 mL	0.6306 mL
	100 mM	0.0202 mL	0.1009 mL	0.2018 mL	0.5045 mL

Keywords

PHGDH-IN-3

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PHGDH-IN-3

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Cancer Metabolism Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) PHGDH-IN-3

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PHGDH-IN-3

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Orally Active Compound Library

Anti-Cancer Metabolism Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) PHGDH-IN-3

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PHGDH-IN-3 Related Classifications

HY-148570 Related Classifications